Cite

    Jones, J., Lee, D., Smukste, I., Cui, D., Bursavich, M. G., Troast, D., Zhong, C., Wong, J. E., Mangada, M. M., Bain, G., Lippa, B., Ray, A. S., & Rogers, B. N. (n.d.). p037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor. Journal of Crohn's and colitis, 15, S149–S150. http://access.bl.uk/ark:/81055/vdc_100130765682.0x000007